Literature DB >> 33033993

Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1.

Ankita Narayan1, Amanda Hunkele1, Jin Xu1, Daniel L Bassoni2, Gavril W Pasternak1, Ying-Xian Pan3,4.   

Abstract

The biased signaling has been extensively studied in the original mu opioid receptor (MOR-1), particularly through G protein and β-arrestin2 signaling pathways. The concept that the G protein pathway is often linked to the therapeutic effect of the drug, while the β-arrestin pathway is associated to the side effects has been proposed to develop biased analgesic compounds with limited side-effects associated with traditional opiates. The mu opioid receptor gene, OPRM1, undergoes extensive alternative pre-mRNA splicing, generating multiple splice variants or isoforms that are conserved from rodent to human. One type of the Oprm1 splice variants are the full-length 7 transmembrane (7TM) C-terminal splice variants, which have identical receptor structures including entire binding pocket, but contain a different intracellular C-terminal tail resulted from 3' alternative splicing. Increasing evidence suggest that these full-length 7TM C-terminal variants play important roles in mu opioid pharmacology, raising questions regarding biased signaling at these multiple C-terminal variants. In the present study, we investigated the effect of different C-terminal variants on mu agonist-induced G protein coupling, β-arrestin2 recruitment, and ultimately, signaling bias. We found that mu agonists produced marked differences in G protein activation and β-arrestin2 recruitment among various C-terminal variants, leading to biased signaling at various level. Particularly, MOR-1O, an exon 7-associated variant, showed greater β-arrestin2 bias for most mu agonists than MOR-1, an exon 4-associated variant. Biased signaling of G protein-coupled receptors has been defined by evidences that different agonists can produce divergent signaling transduction pathways through a single receptor. Our findings that a single mu agonist can induce differential signaling through multiple 7TM splice variants provide a new perspective on biased signaling at least for Oprm1, which perhaps is important for our understanding of the complex mu opioid actions in vivo where all the 7TM splice variants co-exist.

Entities:  

Keywords:  Beta-arrestin; Biased signaling; G-protein; Mu opioid receptor; Splicing

Mesh:

Substances:

Year:  2020        PMID: 33033993      PMCID: PMC8026774          DOI: 10.1007/s10571-020-00973-5

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   4.231


  34 in total

1.  NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells.

Authors:  Andrew S Dixon; Marie K Schwinn; Mary P Hall; Kris Zimmerman; Paul Otto; Thomas H Lubben; Braeden L Butler; Brock F Binkowski; Thomas Machleidt; Thomas A Kirkland; Monika G Wood; Christopher T Eggers; Lance P Encell; Keith V Wood
Journal:  ACS Chem Biol       Date:  2015-12-10       Impact factor: 5.100

2.  A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation.

Authors:  L S Barak; S S Ferguson; J Zhang; M G Caron
Journal:  J Biol Chem       Date:  1997-10-31       Impact factor: 5.157

3.  Differential expression of the alternatively spliced OPRM1 isoform μ-opioid receptor-1K in HIV-infected individuals.

Authors:  Seth M Dever; Blair N Costin; Ruqiang Xu; Nazira El-Hage; Joyce Balinang; Alexander Samoshkin; Megan A O'Brien; Marypeace McRae; Luda Diatchenko; Pamela E Knapp; Kurt F Hauser
Journal:  AIDS       Date:  2014-01-02       Impact factor: 4.177

4.  Phosphorylation of unique C-terminal sites of the mu-opioid receptor variants 1B2 and 1C1 influences their Gs association following chronic morphine.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; Alan R Gintzler
Journal:  J Neurochem       Date:  2019-10-20       Impact factor: 5.372

5.  Differential expression and HIV-1 regulation of μ-opioid receptor splice variants across human central nervous system cell types.

Authors:  Seth M Dever; Ruqiang Xu; Sylvia Fitting; Pamela E Knapp; Kurt F Hauser
Journal:  J Neurovirol       Date:  2012-04-20       Impact factor: 2.643

Review 6.  Beta galactosidase enzyme fragment complementation as a novel technology for high throughput screening.

Authors:  Richard M Eglen; Rajendra Singh
Journal:  Comb Chem High Throughput Screen       Date:  2003-06       Impact factor: 1.339

7.  The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS).

Authors:  Lucie Bertrand; Stéphane Parent; Mireille Caron; Mireille Legault; Erik Joly; Stéphane Angers; Michel Bouvier; Mike Brown; Benoit Houle; Luc Ménard
Journal:  J Recept Signal Transduct Res       Date:  2002 Feb-Nov       Impact factor: 2.092

8.  Dysregulated expression of the alternatively spliced variant mRNAs of the mu opioid receptor gene, OPRM1, in the medial prefrontal cortex of male human heroin abusers and heroin self-administering male rats.

Authors:  Taylor G Brown; Jin Xu; Yasmin L Hurd; Ying-Xian Pan
Journal:  J Neurosci Res       Date:  2020-06-07       Impact factor: 4.164

9.  Biased Signaling of the Mu Opioid Receptor Revealed in Native Neurons.

Authors:  Aliza T Ehrlich; Meriem Semache; Florence Gross; Dillon F Da Fonte; Leonie Runtz; Christine Colley; Amina Mezni; Christian Le Gouill; Viktoriya Lukasheva; Mireille Hogue; Emmanuel Darcq; Michel Bouvier; Brigitte L Kieffer
Journal:  iScience       Date:  2019-03-15

10.  Differential regulation of Cav2.2 channel exon 37 variants by alternatively spliced μ-opioid receptors.

Authors:  Maria A Gandini; Ivana A Souza; Dvij Raval; Jin Xu; Ying-Xian Pan; Gerald W Zamponi
Journal:  Mol Brain       Date:  2019-11-27       Impact factor: 4.041

View more
  5 in total

Review 1.  Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases.

Authors:  Orkid Coskuner-Weber; Ozan Mirzanli; Vladimir N Uversky
Journal:  Biophys Rev       Date:  2022-06-08

Review 2.  Strategies towards safer opioid analgesics-A review of old and upcoming targets.

Authors:  Balazs R Varga; John M Streicher; Susruta Majumdar
Journal:  Br J Pharmacol       Date:  2021-11-26       Impact factor: 9.473

Review 3.  Alternative Pre-mRNA Splicing of the Mu Opioid Receptor Gene, OPRM1: Insight into Complex Mu Opioid Actions.

Authors:  Shan Liu; Wen-Jia Kang; Anna Abrimian; Jin Xu; Luca Cartegni; Susruta Majumdar; Patrick Hesketh; Alex Bekker; Ying-Xian Pan
Journal:  Biomolecules       Date:  2021-10-15

Review 4.  From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks.

Authors:  Nikolai Jaschke; Sophie Pählig; Ying-Xian Pan; Lorenz C Hofbauer; Andy Göbel; Tilman D Rachner
Journal:  Trends Endocrinol Metab       Date:  2021-03-03       Impact factor: 12.015

Review 5.  Exploring Pharmacological Functions of Alternatively Spliced Variants of the Mu Opioid Receptor Gene, Oprm1, via Gene-Targeted Animal Models.

Authors:  Wenjian Kang; Shan Liu; Jin Xu; Anna Abrimian; Ayma F Malik; Raymond Chien; Adejuyigbe Adaralegbe; Akwasi Amponsah; Luca Cartegni; John Pintar; Ying-Xian Pan
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.